Koji Matsuo1, Hiroko Machida2, Tsuyoshi Takiuchi2, Brendan H Grubbs3, Lynda D Roman4, Anil K Sood5, David M Gershenson5. 1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. Electronic address: koji.matsuo@med.usc.edu. 2. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA. 3. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA. 4. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. 5. Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract
OBJECTIVE: To examine survival of women with stage T1 borderline ovarian tumors (BOTs) stratified by hysterectomy and lymphadenectomy status at surgery. METHODS: This is a retrospective study examining The Surveillance, Epidemiology, and End Results Program to identify surgically-treated stage T1 BOTs between 1988 and 2003 (n=4943). Association of surgery patterns and cause-specific survival (CSS) was examined in multivariable analysis. RESULTS: Mean age was 48.7. The majority had stage T1a disease (75.3%). Median follow-up was 15.6years and 159 (3.2%) women died of BOTs. Hysterectomy and lymphadenectomy were performed in 1909 (38.6%) and 1295 (26.2%) cases, respectively. Most commonly, neither procedure was performed (46.5%), followed by hysterectomy alone (27.3%), lymphadenectomy alone (14.9%), and both procedures (11.3%). Surgery patterns for hysterectomy and lymphadenectomy significantly differed across age, ethnicity, marital status, registry area, year at diagnosis, histology type, sub-stage, and tumor size (all, P<0.001). On multivariable analysis, surgery patterns for hysterectomy and lymphadenectomy were not associated with CSS: 20-year rates for neither hysterectomy and lymphadenectomy 96.7%, hysterectomy alone 94.5%, lymphadenectomy alone 95.7%, and both procedures 95.2% (adjusted-P>0.05). Age≥50, T1b-c stages, and mucinous histology remained independent prognostic factors for decreased CSS (all, P<0.05). Among 3723 women with stage T1a disease, hysterectomy and lymphadenectomy patterns were not associated with CSS in 2115 women aged <50 (P=0.14) and 1608 women aged ≥50 (P=0.48). CONCLUSION: Our study suggests that both hysterectomy and lymphadenectomy may be omitted in the surgical management of women with stage T1 BOTs, especially for those with T1a disease regardless of age. Copyright Â
OBJECTIVE: To examine survival of women with stage T1 borderline ovarian tumors (BOTs) stratified by hysterectomy and lymphadenectomy status at surgery. METHODS: This is a retrospective study examining The Surveillance, Epidemiology, and End Results Program to identify surgically-treated stage T1 BOTs between 1988 and 2003 (n=4943). Association of surgery patterns and cause-specific survival (CSS) was examined in multivariable analysis. RESULTS: Mean age was 48.7. The majority had stage T1a disease (75.3%). Median follow-up was 15.6years and 159 (3.2%) women died of BOTs. Hysterectomy and lymphadenectomy were performed in 1909 (38.6%) and 1295 (26.2%) cases, respectively. Most commonly, neither procedure was performed (46.5%), followed by hysterectomy alone (27.3%), lymphadenectomy alone (14.9%), and both procedures (11.3%). Surgery patterns for hysterectomy and lymphadenectomy significantly differed across age, ethnicity, marital status, registry area, year at diagnosis, histology type, sub-stage, and tumor size (all, P<0.001). On multivariable analysis, surgery patterns for hysterectomy and lymphadenectomy were not associated with CSS: 20-year rates for neither hysterectomy and lymphadenectomy 96.7%, hysterectomy alone 94.5%, lymphadenectomy alone 95.7%, and both procedures 95.2% (adjusted-P>0.05). Age≥50, T1b-c stages, and mucinous histology remained independent prognostic factors for decreased CSS (all, P<0.05). Among 3723 women with stage T1a disease, hysterectomy and lymphadenectomy patterns were not associated with CSS in 2115 women aged <50 (P=0.14) and 1608 women aged ≥50 (P=0.48). CONCLUSION: Our study suggests that both hysterectomy and lymphadenectomy may be omitted in the surgical management of women with stage T1 BOTs, especially for those with T1a disease regardless of age. Copyright Â
Authors: K K Shih; Q Zhou; J Huh; J C Morgan; A Iasonos; C Aghajanian; D S Chi; R R Barakat; N R Abu-Rustum Journal: Gynecol Oncol Date: 2010-12-10 Impact factor: 5.482
Authors: M Marchionni; G L Bracco; V Checcucci; A Carabaneanu; E M Coccia; F Mecacci; G Scarselli Journal: J Reprod Med Date: 1999-08 Impact factor: 0.142
Authors: Kathleen M Schmeler; Xia Tao; Michael Frumovitz; Michael T Deavers; Charlotte C Sun; Anil K Sood; Jubilee Brown; David M Gershenson; Pedro T Ramirez Journal: Obstet Gynecol Date: 2010-08 Impact factor: 7.661
Authors: Andreas du Bois; Nina Ewald-Riegler; Nikolaus de Gregorio; Alexander Reuss; Sven Mahner; Christina Fotopoulou; Friedrich Kommoss; Barbara Schmalfeldt; Felix Hilpert; Tanja Fehm; Alexander Burges; Werner Meier; Peter Hillemanns; Lars Hanker; Annette Hasenburg; Hans-Georg Strauss; Martin Hellriegel; Pauline Wimberger; Mignon-Denise Keyver-Paik; Klaus Baumann; Ulrich Canzler; Kerstin Wollschlaeger; Dirk Forner; Jacobus Pfisterer; Willibald Schröder; Karsten Münstedt; Barbara Richter; Stefan Kommoss; Steffen Hauptmann Journal: Eur J Cancer Date: 2013-03-13 Impact factor: 9.162
Authors: Gautam G Rao; Elizabeth Skinner; Paola A Gehrig; Linda R Duska; Robert L Coleman; John O Schorge Journal: Obstet Gynecol Date: 2004-08 Impact factor: 7.661
Authors: Mark E Sherman; Pamela J Mink; Rochelle Curtis; Timothy R Cote; Sandra Brooks; Patricia Hartge; Susan Devesa Journal: Cancer Date: 2004-03-01 Impact factor: 6.860
Authors: Jaimin S Shah; Michael Mackelvie; David M Gershenson; Preetha Ramalingam; Marylee M Kott; Jubilee Brown; Polly Gauthier; Elizabeth Nugent; Lois M Ramondetta; Michael Frumovitz Journal: J Minim Invasive Gynecol Date: 2018-04-19 Impact factor: 4.137
Authors: David J Nusbaum; Rachel S Mandelbaum; Hiroko Machida; Shinya Matsuzaki; Lynda D Roman; Anil K Sood; David M Gershenson; Koji Matsuo Journal: Arch Gynecol Obstet Date: 2020-04-17 Impact factor: 2.344
Authors: Koji Matsuo; Hiroko Machida; Brendan H Grubbs; Shinya Matsuzaki; Maximilian Klar; Lynda D Roman; Anil K Sood; David M Gershenson Journal: Gynecol Oncol Date: 2020-01-15 Impact factor: 5.482